Skip to Content
Upcoming Webinar

A Pharmacist’s Perspectives on Emerging Trends in AML

Date: August 20, 2025 | 2:00 PM
Date: Wednesday, August 20, 2025
Time: 2 pm & 5 pm EST

In acute myeloid leukemia (AML), mutation testing at diagnosis can mean the difference between timely access to targeted therapies and missed opportunities. For mutations linked to the menin pathway, early identification is essential for guiding treatment sequencing and eligibility for emerging therapies.

In this special double-feature session, Jessica Freydman, PharmD, BCOP will share a pharmacist’s perspective on integrating mutation testing into AML workflows, interpreting results in treatment planning, and managing patients on novel targeted therapies in community settings.

What You’ll Learn

  • How and when to incorporate early mutation testing into AML workflows
  • Key biomarkers to identify, including those tied to the menin pathway
  • Strategies to interpret results and guide sequencing decisions
  • Approaches to overcoming access barriers for targeted therapies
  • Best practices for managing toxicities and ensuring adherence

For additional information or login assistance, reach out to NCODA’s Jonathan Rivera.